| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Crotedumab (anti-GCGR)
CAS:1452387-69-7
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:100μg Remarks:K13634
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Crotedumab
CAS:1452387-69-7
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Crotedumab
CAS:1452387-69-7
Purity:95% Package:1mg;1g;100g
|
|
| | Crotedumab Basic information |
| Product Name: | Crotedumab | | Synonyms: | Crotedumab;Research Grade Crotedumab(DHE51802);REGN1193;Research Grade Crotedumab;Crotedumab (anti-GCGR) | | CAS: | 1452387-69-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Crotedumab Structure]() |
| | Crotedumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Crotedumab Usage And Synthesis |
| Uses | Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes[1][2]. | | in vivo | Crotedumab (3-30 mg/kg; s.c. once weekly for 4 weeks) reduces blood glucose and body weight and induces reversible hyperglucagonemia and α-cell hyperplasia in DIO C57BL/6 mice[2].
Crotedumab (10 mg/kg; a single s.c.) markedly decreases blood glucose for 18 days in diabetic ob/ob mice[2].
REGN1193 (20 mg/kg; a single i.v.) produces a robust reduction in overnight-fasted blood glucose in both the conscious and anesthetized state of diabetic cynomolgus monkeys as well as in blood glucose measured 1 hour after feeding[2]. | Animal Model: | Diet-induced obese (DIO) male C57BL/6NTac mice were maintained on high-fat diet[2] | | Dosage: | 3, 10, 30 mg/kg | | Administration: | S.c. injection once weekly for 4 weeks | | Result: | Markedly reduced blood glucose throughout the dosing period.
Reversibly decreased body weight during the dosing period.
Dose- and time-dependently increased glucagon and GLP-1.
Reversibly increased α-cell area.
|
| | References | [1] Kostic A, et, al. A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers. Diabetes Obes Metab. 2018 Feb;20(2):283-291. DOI:10.1111/dom.13075
[2] Okamot H, et, al. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys. Endocrinology. 2015 Aug;156(8):2781-94. DOI:10.1210/en.2015-1011 |
| | Crotedumab Preparation Products And Raw materials |
|